800 - 460 - 5832


Melanoma, Metastatic Lung, and Kidney Cancer Patients a Step Closer to Receiving Immunotherapy!
Feb 16, 2017

As of this week, melanoma, metastatic lung, and kidney cancer patients are a step closer to receiving immunotherapy treatments. The pan-Canadian Pharmaceutical Alliance (pCPA) has reached a pricing agreement with Bristol Myers-Squibb for nivolumab (OPDIVO®), bringing the drug closer to being publicly funded and listed on provincial formularies for some patients. More information can be found here.

Share Button